NICE rejects Roche's Avastin for metastatic colorectal cancer, again
This article was originally published in Scrip
Executive Summary
NICE, the National Institute of health and Clinical Excellence in England and Wales, has again rejected Roche's Avastin (bevacizumab) for metastatic colorectal cancer. An amended patient access scheme submitted by the company failed to convince the institute that the drug would be a cost-effective use of NHS resources.